Rough Titanium Oxide Coating Prepared by Micro-Arc Oxidation Causes Down-Regulation of hTERT Expression, Molecular Presentation, and Cytokine Secretion in Tumor Jurkat T Cells; Materials; Vol. 11, iss. 3
| Parent link: | Materials Vol. 11, iss. 3.— 2018.— [360, 18 p.] |
|---|---|
| Autor Corporativo: | |
| Outros autores: | , , , , , , , , , |
| Summary: | Title screen The response of the human Jurkat T cell leukemia-derived cell line (Jurkat T cells) after 24 h of in vitro exposure to a titanium substrate (12•12•1 mm[mu]) with a bilateral rough (Ra=2.2-3.7 [mu]m) titanium oxide coating (rTOC) applied using the micro-arc method in a 20% orthophosphoric acid solution was studied. A 1.5-fold down-regulation of hTERT mRNA expression and decreases in CD3, CD4, CD8, and CD95 presentation and IL-4 and TNF[alpha] secretion were observed. Jurkat T cell inactivation was not correlated with the generation of intracellular reactive oxygen species (ROS) and was not mediated by TiO? nanoparticles with a diameter of 14 ± 8 nm at doses of 1 mg/L or 10 mg/L. The inhibitory effect of the rTOC (Ra=2.2-3.7 [mu]m) on the survival of Jurkat T cells (Spearman's coefficient rs=-0.95; n=9; p<0.0001) was demonstrated by an increase in the necrotic cell count among the cell population. In turn, an elevation of the Ra index of the rTOC was accompanied by a linear increase (r=0.6; p<0.000001, n=60) in the magnitude of the negative electrostatic potential of the titanium oxide surface. Thus, the roughness of the rTOC induces an electrostatic potential and decreases the viability of the immortalized Jurkat T cells through mechanisms unrelated to ROS generation. This may be useful for replacement surgery applications of rough TiO2 implants in cancer patients. |
| Idioma: | inglés |
| Publicado: |
2018
|
| Subjects: | |
| Acceso en liña: | https://doi.org/10.3390/ma11030360 |
| Formato: | MixedMaterials Electrónico Capítulo de libro |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=667038 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 667038 | ||
| 005 | 20250303140027.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\38242 | ||
| 035 | |a RU\TPU\network\37940 | ||
| 090 | |a 667038 | ||
| 100 | |a 20220217d2018 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a CH | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a Rough Titanium Oxide Coating Prepared by Micro-Arc Oxidation Causes Down-Regulation of hTERT Expression, Molecular Presentation, and Cytokine Secretion in Tumor Jurkat T Cells |f I. A. Khlusov, L. S. Litvinova, V. V. Shupletsova [et al.] | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 320 | |a [References: 57 tit.] | ||
| 330 | |a The response of the human Jurkat T cell leukemia-derived cell line (Jurkat T cells) after 24 h of in vitro exposure to a titanium substrate (12•12•1 mm[mu]) with a bilateral rough (Ra=2.2-3.7 [mu]m) titanium oxide coating (rTOC) applied using the micro-arc method in a 20% orthophosphoric acid solution was studied. A 1.5-fold down-regulation of hTERT mRNA expression and decreases in CD3, CD4, CD8, and CD95 presentation and IL-4 and TNF[alpha] secretion were observed. Jurkat T cell inactivation was not correlated with the generation of intracellular reactive oxygen species (ROS) and was not mediated by TiO? nanoparticles with a diameter of 14 ± 8 nm at doses of 1 mg/L or 10 mg/L. The inhibitory effect of the rTOC (Ra=2.2-3.7 [mu]m) on the survival of Jurkat T cells (Spearman's coefficient rs=-0.95; n=9; p<0.0001) was demonstrated by an increase in the necrotic cell count among the cell population. In turn, an elevation of the Ra index of the rTOC was accompanied by a linear increase (r=0.6; p<0.000001, n=60) in the magnitude of the negative electrostatic potential of the titanium oxide surface. Thus, the roughness of the rTOC induces an electrostatic potential and decreases the viability of the immortalized Jurkat T cells through mechanisms unrelated to ROS generation. This may be useful for replacement surgery applications of rough TiO2 implants in cancer patients. | ||
| 461 | |t Materials | ||
| 463 | |t Vol. 11, iss. 3 |v [360, 18 p.] |d 2018 | ||
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a TiO2 nanoparticles | |
| 610 | 1 | |a in vitro | |
| 610 | 1 | |a reactive oxygen species | |
| 610 | 1 | |a surface electrostatic potential | |
| 610 | 1 | |a titanium substrate | |
| 610 | 1 | |a tumor cell death | |
| 610 | 1 | |a наночастицы | |
| 610 | 1 | |a активные формы | |
| 610 | 1 | |a электростатические потенциалы | |
| 610 | 1 | |a титановые подложки | |
| 610 | 1 | |a опухолевые клетки | |
| 610 | 1 | |a кислород | |
| 701 | 1 | |a Khlusov |b I. A. |c biophysicist |c Professor of Tomsk Polytechnic University, doctor of medical Sciences |f 1963- |g Igor Albertovich |3 (RuTPU)RU\TPU\pers\34907 |9 18225 | |
| 701 | 1 | |a Litvinova |b L. S. | |
| 701 | 1 | |a Shupletsova |b V. V. |g Valeria | |
| 701 | 1 | |a Khaziakhmatova |b O. G. | |
| 701 | 1 | |a Melashchenko |b E. S. | |
| 701 | 1 | |a Yurova |b K. A. | |
| 701 | 1 | |a Leitsin |b V. N. | |
| 701 | 1 | |a Khlusova |b M. Yu. |g Marina Yurjevna | |
| 701 | 1 | |a Pichugin |b V. F. |g Vladimir Fedorovich | |
| 701 | 1 | |a Sharkeev |b Yu. P. |c physicist |c Professor of Tomsk Polytechnic University, Doctor of physical and mathematical sciences |f 1950- |g Yury Petrovich |3 (RuTPU)RU\TPU\pers\32228 |9 16228 | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет |b Исследовательская школа химических и биомедицинских технологий |c (2017- ) |3 (RuTPU)RU\TPU\col\23537 |
| 801 | 2 | |a RU |b 63413507 |c 20220217 |g RCR | |
| 856 | 4 | |u https://doi.org/10.3390/ma11030360 | |
| 942 | |c CF | ||